NewAmsterdam Pharma (NAMS) Interest & Investment Income (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Interest & Investment Income of $5.6 million for Q1 2026, down 23.14% on a YoY basis from $7.4 million in Q1 2025, and down 79.39% sequentially from $27.4 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Interest & Investment Income (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Interest & Investment Income data on file, last reported at $5.6 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 23.14% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $40.4 million (up 837.56% YoY), and the FY2025 full-year result was $27.6 million, up 61215.56% from the prior year.
- Interest & Investment Income slipped to $5.6 million in Q1 2026, from $27.4 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $27.4 million in Q4 2025 to a low of -$12.4 million in Q4 2024.
- A 4-year average of $4.5 million and a median of $4.4 million in 2024 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income slumped 562.93% in 2024 and jumped 322.0% in 2025, its largest moves.
- Tracing NAMS's Interest & Investment Income over 4 years: stood at $2.7 million in 2023, then tumbled by 562.93% to -$12.4 million in 2024, then jumped by 322.0% to $27.4 million in 2025, then sank by 79.39% to $5.6 million in 2026.
- Business Quant data shows NAMS's Interest & Investment Income at $5.6 million in Q1 2026, $27.4 million in Q4 2025, and $313000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | NewAmsterdam Pharma | 3.68 Bn | 3.68 Bn | - | 5.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.65 Mn |
| Dec 31, 2025 | 27.42 Mn |
| Sep 30, 2025 | 313,000.00 |
| Jun 30, 2025 | 7.06 Mn |
| Mar 31, 2025 | 7.35 Mn |
| Dec 31, 2024 | -12.35 Mn |
| Sep 30, 2024 | 4.44 Mn |
| Jun 30, 2024 | 4.87 Mn |
| Mar 31, 2024 | 3.08 Mn |
| Dec 31, 2023 | 2.67 Mn |
| Sep 30, 2023 | 3.06 Mn |
| Jun 30, 2023 | 4.61 Mn |
| Mar 31, 2023 | 943,000.00 |